Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes.
Persistent Staphylococcus aureus bacteremia (SAB) is defined based on varying duration in literature. The primary objective of this large cohort study was to determine the risk for poor outcomes in relation to bacteremia duration. This was a multicenter, prospective, observational study of adult, hospitalized patients with SAB. Medical records were reviewed for pertinent data. Patients were grouped by bacteremia duration: short (1-2d), intermediate (3-6d), and prolonged (≥7d) and compared for risk factors and outcomes. Of 884 patients, 63% had short, 28% intermediate, and 9% prolonged bacteremia. Overall mean age was 57y and 70% were male. Prolonged group had the highest proportion of methicillin-resistant SAB (p<0.0001). Choice of antibiotic therapy did not significantly affect bacteremia duration, however time to source control procedure was delayed in the prolonged and intermediate groups compared to the short group [3.5d vs 3d vs 1d, p<0.0001]. Metastatic complications (12% vs 23% vs 33%), length of stay (9d vs 12d vs 24d), and 30-day mortality (5% vs 11% vs 22%) were progressively worse as bacteremia duration increased (p<0.0001). Every continued day of bacteremia was associated with RR of death of 1.16 (95% CI 1.10-1.22, p<0.0001), with significant increase in risk starting at 3 days as determined by ROC analysis. Optimal management of SAB should target bacterial clearance as soon as possible to minimize incremental risk of mortality with each day of positive blood culture. Delay in source control but not type of anti-staphylococcal therapy was significantly associated with prolonged bacteremia and worse outcomes.